Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapy.
Animals
Antineoplastic Agents, Phytogenic
/ pharmacology
Apoptosis
/ drug effects
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Female
Humans
Male
Naphthoquinones
/ pharmacology
Neoplasms
/ drug therapy
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
Cancer
Cytotoxicity
Drug resistance
Pharmaceuticals applications
Plumbagin
Journal
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
ISSN: 1873-6351
Titre abrégé: Food Chem Toxicol
Pays: England
ID NLM: 8207483
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
31
10
2018
revised:
04
01
2019
accepted:
20
01
2019
pubmed:
28
1
2019
medline:
21
5
2019
entrez:
28
1
2019
Statut:
ppublish
Résumé
Plumbagin is a naphthoquinone derived yellow crystalline phytochemical. Plumbagin has a wide range of biological effects including cytotoxicity against cancer cells both in vitro and in vivo. Due to the pleiotropic nature of plumbagin, it shows the anticancer effect by targeting several molecular mechanisms including apoptosis and autophagic pathways, cell cycle arrest, anti-angiogenic pathways, anti-invasion and anti-metastasis pathways. Among many signaling pathways the key regulatory genes regulated by plumbagin are NF-kβ, STAT3, and AKT, etc. Plumbagin is also a potent inducer of ROS, suppressor of cellular glutathione, and causes DNA strand break by oxidative DNA base damages. In vivo studies suggested that plumbagin significantly reduces the tumor weight and volume in dose-dependent manner without any side effects in tested model organisms. Another exciting aspect of plumbagin is the ability to re-sensitize the chemo and radioresistant cancer cells when used in combination or alone. Nano encapsulation of plumbagin overcomes the poor water solubility and bioavailability obstacles, enhancing the pharmaceutical relevance with better therapeutic efficacy. Moreover, plumbagin can be introduced as a future phytotherapeutic anticancer drug after fully satisfied preclinical and clinical trials.
Identifiants
pubmed: 30685472
pii: S0278-6915(19)30020-1
doi: 10.1016/j.fct.2019.01.018
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Naphthoquinones
0
Reactive Oxygen Species
0
plumbagin
YAS4TBQ4OQ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
566-582Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.